imatinib mesylate has been researched along with Anemia, Hemolytic in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Gronkowska, A; Lakomy, M; Michalewska, B; Pogorzala, M; Rokicka, M; Styczynski, J; Tomaszewska, A; Torosian, T; Wiktor-Jedrzejczak, W; Wysocki, M | 1 |
| De Arriba, JJ; García, E; Gómez-Aldaraví, L; Nerín, C; Vila, B | 1 |
| Chamone, Dde A; Conchon, M; Dorlhiac-Llacer, PE; Fonseca, GH; Novaretti, MC | 1 |
1 review(s) available for imatinib mesylate and Anemia, Hemolytic
| Article | Year |
|---|---|
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
3 other study(ies) available for imatinib mesylate and Anemia, Hemolytic
| Article | Year |
|---|---|
Fatal combined immune hemolytic anemia after double cord blood transplantation in imatinib-resistant CML.
Topics: Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Antibodies, Anti-Idiotypic; Antineoplastic Agents; Benzamides; Cord Blood Stem Cell Transplantation; Cyclosporine; Drug Resistance, Neoplasm; Fatal Outcome; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Splenectomy; Transfusion Reaction; Transplantation Conditioning; Young Adult | 2009 |
Severe hemolytic anemia and skin reaction in a patient treated with imatinib.
Topics: Adrenal Gland Neoplasms; Anemia, Hemolytic; Antineoplastic Agents; Benzamides; Exanthema; Female; Humans; Imatinib Mesylate; Liver Neoplasms; Middle Aged; Piperazines; Pyrimidines; Risk Factors; Splenic Neoplasms; Stomach Neoplasms | 2003 |
First case of immune-mediated haemolytic anaemia associated to imatinib mesylate.
Topics: Anemia, Hemolytic; Benzamides; Coombs Test; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Piperazines; Prednisone; Pyrimidines | 2003 |